IMRX NASDAQ
Credit Risk of going bust: lower than 52% of companies Debt: 1.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.7%), Immuneering Corporation would be worth roughly what it owes.
Total debt $3.6M against a stock market value of $247.8M.
Distance to default 5.27 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.8M (short-term plus half of long-term), stock volatility 87.6%; Altman Z'' 15.49. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Cambridge, MA 02142
US
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Gengos Andrew | A-Award | 650,000 | $4.78 | 2026-07-16 |
| Gengos Andrew | 0 | — | 2026-07-16 | |
| Zeskind Benjamin J. | P-Purchase | 2,400 | $4.56 | 2026-06-23 |
| Hall Brett Matthew | P-Purchase | 6,035 | $4.15 | 2026-06-15 |
| CARPENTER ROBERT J | A-Award | 33,350 | $4.12 | 2026-06-11 |